The CDSCO claims that in addition to pharmaceuticals, the list also contains medical devices and cosmetics that are either of subpar quality or are fake, contaminated, or mislabeled.
Digital Desk: As many as 48 regularly used medicines were highlighted by the Central Drugs Standard Control Organisation (CDSCO) after failing the most recent drug safety tests in March.
From a total of 1,497 samples tested, the top health regulator in the nation marked medications for blood pressure, diabetes, folic acid, multivitamins, antibiotics, and diabetes in the list, representing a failure rate of above 3%.
The list also includes some well-known medications such as Amoxycillin (used for epilepsy), Gabapentin (used for epilepsy), Telmisartan (used for hypertension), Glimepiride and Metformin (used for diabetes), and Ritonavir (used for HIV).
The CDSCO claims that in addition to pharmaceuticals, the list also contains medical devices and cosmetics that are either of subpar quality or are fake, contaminated, or mislabeled. The products that were highlighted, though, were deemed to be of poor quality.
These medications are produced by both private and public pharmaceutical companies, including PSU Karnataka Antibiotics and Pharmaceuticals, Synokem Pharmaceuticals in Uttarakhand, Nestor Pharmaceuticals in Haryana, JBJM Parenterals in Uttar Pradesh, Ronam Healthcare in Solan, and Glenmark Pharmaceuticals in Mumbai.
Drug producers publish notices
Abbott India Limited, meanwhile, announced in a public notice that it has voluntarily recalled one batch of Thyronorm Tablets, which are used to treat hypothyroidism. The letter states that the recalled batch is identified as AEJ0713; Mfg., Date: March 2023.
Patients who recently purchased Thyronorm with batch number AEJ0713; manufacture date: March 2023; expiration date: February 2025 are urged to return the bottle to the pharmacy where they bought it, according to the company's notification.
According to media reports, the corporation further insisted that it was coordinating this recall with partners and distributors.
"Only MP and Telangana have received invoices for this batch. The company noted in the statement, "This issue does not apply to or extend to any other batch or dose strength of Thyronorm or other Abbott medications.
In a separate statement, Glenmark claimed that the TELMA tablets used in the warnings were fake and not made by the company itself.
"After looking into the situation, we discovered that the TELMA AM Tablets (Telmisartan 40 mg and Amlodipine 5 mg Tablets IP) batch number 18220076 from the NSQ list of "March 2023 Month Drugs Alert" are fake drugs that weren't made by Glenmark. In addition to appealing for the substance to be taken off the drug alert list, we have asked the CDSCO to take action on this," the spokeswoman said.
Leave A Comment